Apodex

We invite you to read the full TRACES technical report Inside: the definitions, evaluation rubric, and registry of problems spanning biomedicine, clinical translation, and frontier-model engineering. Led by Apodex Lead Scientist Sheng Wang, the report brings together the technical framework underpinning this effort. Behind it: 10 STEM PhDs, two months of research, and 561 industries surveyed to identify 423 problems worth solving—real, high-stakes questions that can take human experts years to work through. Bring a problem. Bring a solver. Both doors are open. *Submit a Problem: https://lnkd.in/gmurNBMN *Submit a Solver: https://lnkd.in/g7ZsKZzE

Meet Apodex 1.1 ⚡: Scaling Agentic Intelligence for Complex Work We’re excited to introduce Apodex 1.1, our new model family built to scale agentic intelligence for professional work. 🧠 Frontier-level intelligence for complex work Apodex 1.1 brings frontier-level agentic performance across complex professional work, scientific research, financial analysis, and deep search. 🤝 Asynchronous Agent Team Apodex 1.1 can break down complex tasks, coordinate multiple agents in parallel, continuously integrate their findings, and let you step in to guide or redirect the work at any time. 🔬 Open-source research workbench We’re open-sourcing FrontierAgent—a locally deployable research workbench for the Apodex 1.1 family, including asynchronous Agent Team. Where Apodex 1.1 lands: ▸ Professional work — APEX-Agent 38.5 · GDPVal 78.8 win rate ▸ Finance — FrontierFinance 54.3 ▸ Scientific research — FrontierScience-Research 63.3 · BioMysteryBench (Human-difficult) 35.3 ▸ Reasoning — HLE 56.1 Across the four benchmarks evaluated in both ReAct and Agent Team configurations, Agent Team adds 4.1–9.3 points. Available now: 🔹 Apodex 1.1 — our most capable frontier model, available through the Apodex online workbench 🔹 Apodex 1.1 mini — open-weight model for running complex work locally 🔹 FrontierAgent — open-source, locally deployable research workbench Open Source Harness: https://lnkd.in/gA8k3wkE Open Weights: https://lnkd.in/gq3xkMrm Online workbench: https://www.apodex.ai/ API platform: https://lnkd.in/grwQB-te Paper: https://lnkd.in/gQy--prw Blog: https://lnkd.in/gxzAqeHv

Most AI benchmarks test questions that already have an answer key. The hardest, highest-value problems in science, medicine, and engineering are still unsolved — no one knows what a correct answer even looks like. Meet TRACES 🧭 — the world's first standard for measuring discoverative AI: AI directed at reaching conclusions nobody has reached yet. Proposed by our founder Tianqiao Chen 陈天桥, who defined its six capabilities. Before today, "AI that makes discoveries" is just a slogan. Three things published today change that: a definition of "discoverative intelligence", a rubric to tell sound investigation from lucky guesses, and a open call for both solvers and problems. WHAT TRACES MEASURES Not just the answer, but the path to the answer. Six capabilities that spell its name: T — Tools: selecting, calling and correctly interpreting external tools R — Repair: locating and correcting its own errors once feedback arrives A — Alternatives: laying out competing hypotheses and keeping or discarding them as evidence accumulates C — Coherence: holding state, constraints and logic intact across a long chain of work E — Evidence: grounding every conclusion in observation, data, experiment or citation S — Scope: stating the conditions under which a conclusion holds, and where it does not apply TRACES evaluates today whether the discovery process is rigorous and evidence-grounded, even when the final outcome is not yet known 🔍 WHAT IS PUBLISHED TODAY Today, in full: the technical report — the definitions, the rubric, the registry of problems — spanning biomedicine, clinical translation and frontier-model engineering. Led by Apodex’s Lead Scientist Sheng Wang, who brings together the technical framework behind this effort. Behind them: 10 STEM PhDs, two months, 561 industries surveyed to find the 423 problems worth doing this for. Bring a problem. Bring a solver. Both doors are open. 📄 Paper : https://lnkd.in/gv7V-Arg 🌐 Website https://traces.apodex.com/ #AIforScience #ScientificDiscovery #AIEvaluation #DrugDiscovery

Advanced AI for drug research, now ✅ FREE for everyone. Small biotech teams have great ideas but lack the AI talent, compute, and tools to pursue them. Apodex is changing that. Use our tools for free, and tell us what we should build next. Try it free: drug.apodexlab.ai

We’re Making Advanced AI Drug Research Free for Everyone At Apodex, our goal is to build Discoverative AI—AI that can help humanity discover things we do not yet know, not just generate answers from what we already know. I believe this is one of the most valuable things AI can do for humanity. And drug research is one of the best places to start. Few things matter more than finding better ways to prevent and treat diseases. There are thousands of small biotech companies and research teams working on important medical problems. Many have good ideas but do not have enough AI experts, computing resources, or research tools to explore them. I don’t think a good scientific idea should have to wait for a big budget. That is why we decided to make a growing set of Apodex’s AI drug research tools available for free. One thing I want to emphasize: we are offering much more than free computing. At Apodex, we have a team of scientists and AI researchers who are constantly improving our models, algorithms, and research tools. We are starting with clinical trial forecasting, drug repurposing, drug interactions, and safety assessment. But this is just the beginning. What matters even more is what you need that we have not built yet. We want to listen and develop new tools and algorithms based on real research needs. Some may become free tools for everyone, while others may require deeper collaboration. Our goal is to make useful AI research capabilities available to more people, while continuing to build better ones. So please don’t just come to Apodex to use what we have built for free. Come and tell us what we should build next. https://drug.apodexlab.ai/ #AIforScience #DrugDiscovery #Apodex

Four days ago, we put Apodex 1.1 Mini on OpenRouter. Today it’s #4 on OpenRouter’s New & Trending list 🎊, with 79.6B tokens processed. That puts it next to new releases from Anthropic and OpenAI. Token volume is a simple metric, but an honest one. It shows developers choosing a model for real workloads. A quick recap of Apodex 1.1 Mini: 🔷 A reasoning-first model built for research, forecasting, and agentic workflows 🔷 262K context window 🔷 Available now on OpenRouter Thank you to everyone who’s been putting it to work. More from the Apodex model family soon. If you’re building research or reasoning workflows, give it a run and tell us what you find 👇 https://lnkd.in/g3bwJRSc #Apodex #OpenRouter #LLM #AIAgents #AIforDiscovery